National Cholesterol Education Program Research Articles

Metabolic phenotype and risk of obesity-related cancers in the Women's Health Initiative.

Body mass index (BMI) may misclassify obesity-related cancer (ORC) risk, as metabolic dysfunction can occur across BMI levels. We hypothesized that metabolic dysfunction at any BMI increases ORC risk compared to normal BMI without metabolic dysfunction. Postmenopausal women (n=20,593) in the Women's Health Initiative with baseline metabolic dysfunction biomarkers (blood pressure, fasting triglycerides, high-density lipoprotein-cholesterol, fasting glucose, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and high sensitive C-reactive protein (hs-CRP)) were included. Metabolic phenotype (metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy overweight/obese (MHO), metabolically unhealthy overweight/obese (MUO)) was classified using four definitions of metabolic dysfunction: (1) Wildman criteria, (2) National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III), (3) HOMA-IR, and (4) hs-CRP. Multivariable Cox proportional hazards regression, with death as a competing risk, was used to assess the association between metabolic phenotype and ORC risk. After a median (IQR) follow-up duration of 21 (IQR 15-22) years, 2,367 women developed an ORC. The risk of any ORC was elevated among MUNW (HR 1.12, 95% CI: 0.90-1.39), MHO (HR 1.15, 95% CI: 1.00-1.32), and MUO (HR 1.35, 95% CI: 1.18-1.54) compared with MHNW using Wildman criteria. Results were similar using ATP III criteria, hs-CRP alone, or HOMA-IR alone to define metabolic phenotype. Individuals with overweight or obesity with or without metabolic dysfunction were at higher risk of ORCs compared with metabolically healthy normal weight individuals. The magnitude of risk was greater among those with metabolic dysfunction, although the confidence intervals of each category overlapped.

Increased dementia risk in patients with Parkinson's disease attributed to metabolic syndrome.

Metabolic syndrome (MetS) manifests resembling pathophysiological mechanisms with Parkinson's disease (PD). Current research on the overall population has emphasized MetS as a freestanding risk factor for cognition. This research aims to explore the impact of MetS on cognition in Parkinson's patients. We involved subjects identified as having early-stage PD patients. The MetS was diagnosed dependent on parameters overviewed in the National Cholesterol Education Program's Adult Treatment Panel III. The clinical severity and stages in patients with PD were dependent on the disease rating scales. The cognition was evaluated by the Turkısh version of the Montreal Cognitive Assessment Scale (MoCA-TR). The cases were categorized according to cognitive failure: mild cognitive impairment in PD (PD-MCI), and PD dementia (PDD). Metabolic syndrome was present in 39.6% of the participants. 22.0% of patients were in the normal cognition, 29.1% in the PD-MCI group, and 48.9% in the PD-D group. The cognitive scores in patients with MetS is considerably lower than MetS negative group. A statistically notable inverse association was detected between fasting blood glucose levels and the visual-spatial/executive functions, naming, language, and orientation scores. The multivariate logistic regression analysis showed individuals with MetS were found to have an 11.308 times higher risk of PD-D (odds ratio [OR]: 11,3, 95% confidence interval [CI]: 1.61-79.2 ). We discerned the occurrence of MetS in PD raises the possibility of advancing dementia. This suggests that considering MetS in this patient group could contribute to the effective management of dementia.

Red cell distribution width/albumin ratio as a marker for metabolic syndrome: findings from a cross-sectional study

BackgroundMetabolic syndrome (MetS) imposes a significant health burden on patients globally. Chronic low-grade inflammation is pivotal in the onset and progression of this condition. However, the role of the novel inflammatory marker, red cell distribution width to albumin ratio (RAR), in the development of MetS remains unclear.MethodsThis population-based cross-sectional study utilized data from the 2011–2020 National Health and Nutrition Examination Survey (NHANES). Participants included individuals over 18 years old with complete data on serum albumin concentration, red cell distribution, and MetS and its components. MetS was defined using the criteria established by the National Cholesterol Education Program Adult Treatment Panel III. The calculation formula for RAR is: RAR = Red cell distribution width (%)/serum albumin (g/dL). Study participants were stratified into four quartiles based on RAR levels. Logistic regression analysis and subgroup analysis were employed to explore the independent interaction between RAR and MetS, as well as investigate the relationship between RAR levels and the specific components of MetS. Finally, the receiver operating characteristic (ROC) curve was used to assess the predictive efficacy of RAR for MetS.ResultsA total of 4899 participants were included in this study, comprising 2450 males and 2449 females; 1715 individuals (35.01%) were diagnosed with MetS. As the quartile of RAR increased, the proportion of individuals with MetS also increased. Spearman correlation analysis indicated a positive correlation between RAR and the insulin resistance index HOMA-IR. Logistic regression analysis, adjusting for multiple confounding factors, showed that each standard deviation increase in RAR was associated with a significant 1.665-fold increase (95% CI, 1.404–1.975; P < 0.001) in the odds of MetS prevalence. In logistic regression analysis stratified by quartiles of RAR, the risks of MetS in Q1-Q4 were 1.372 (95% CI, 1.105–1.704; P = 0.004), 1.783 (95% CI, 1.434–2.216; P < 0.001), and 2.173 (95% CI, 1.729–2.732; P < 0.001), respectively. Subgroup analyses and interaction tests demonstrated that gender, age, race, education, smoking status, and physical activity modified the positive association between RAR and MetS (p for interaction < 0.05). Additionally, analysis of the area under the receiver operating characteristic (ROC) curve showed that the optimal cutoff value for predicting MetS using RAR was 3.1348 (sensitivity: 59.9%; specificity: 60.6%; and AUC: 0.628).ConclusionsIncreasing RAR levels are associated with a higher risk of MetS. Therefore, greater attention should be given to patients with high RAR levels for improved prevention and treatment of MetS.

Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.

We determined if metabolic syndrome, its components, and adipokines (adiponectin, leptin, Fibroblast Growth Factor-21) were associated with response to advanced therapies among patients with rheumatoid arthritis (RA). This study included participants with RA initiating either TNFi or non-TNFi biologic therapies from the Comparative Effectiveness Registry to studyTherapies forArthritis andInflammatory Conditions(CERTAIN) cohort within the CorEvitas registry. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III definition. Adipokines were assessed on stored samples from a sub-sample of responders and non-responders (N=200). The primary outcome was the achievement of a change as large as the minimal clinically important difference (MCID) for the Clinical Disease Activity Index (CDAI) at 6 months. Among 2,368 participants, 687 (29%) had metabolic syndrome. Metabolic syndrome was associated with lower odds of achieving CDAI MCID [OR (95% CI): 0.69 (0.56,0.86) p=0.001] with a dose-dependent decrease in response rate according to the number of components present. Model fit was superior for metabolic syndrome compared to BMI. Associations between metabolic syndrome and MCID achievement were similar between patients receiving TNFi [OR (95% CI): 0.65 (0.49,0.87) p=0.003] v. non-TNF therapies [OR (95% CI): 0.76 (0.55,1.04) p=0.08)] (p-for-interaction=0.49). Adipokines were not associated with MCID achievement. Metabolic syndrome is associated with lower response rates with the initiation of an advanced therapy in RA, with similar effects for both TNFi and non-TNFi agents. Adipokines were strongly associated with metabolic syndrome but were not associated with clinical response.

The association between dietary carbohydrate intake and the risk of hyperlipidemia among reproductive-aged women in the US: A cross-sectional study.

The association between dietary carbohydrate intake and hyperlipidemia remained incompletely understood. This study aimed to explore the association between dietary carbohydrate intake and the risk of hyperlipidemia among reproductive-aged women in the US. The study utilized data from the National Health and Nutrition Examination Survey (NHANES) conducted from 2005 to 2020. Dietary intake information was assessed via interviews using 24-hour dietary recall interviews, and hyperlipidemia diagnosis adhered to the National Cholesterol Education Program guidelines. Univariate and multivariate logistic regression analyses, along with restricted cubic splines (RCS) and stratified analyses, were conducted to investigate the association between dietary carbohydrate intake and the risk of hyperlipidemia. A total of 6,791 women of reproductive age, with a mean age of 34.87 (±8.57) years, were included in the final analysis. In the multivariate logistic regression model adjusting for covariates, a higher percentage of energy from carbohydrate was positively correlated with the risk of hyperlipidemia (adjusted odds ratio (AOR): 1.014, 95% CI: 1.004-1.024). Analyzing the percentage of energy from carbohydrate as a categorical variable, compared to the lowest quartile, the third quartile (AOR: 1.263, 95% CI: 1.031-1.546) and the highest quartile (AOR: 1.411, 95% CI: 1.083-1.839) were associated with increased hyperlipidemia risk. Additionally, a linear relationship (P for nonlinearity = 0.088) existed between the percentage of energy from carbohydrate and the risk of hyperlipidemia, with an inflection point identified at 49.64. This study found that elevated dietary carbohydrate intake was associated with an increased the risk of hyperlipidemia in reproductive-aged women. These findings implied that reproductive-aged women should pay closer attention to reducing their carbohydrate intake.

A-217 Estimation of the Prevalence and the Patterns of Dyslipidemia in the Korean population

Abstract Background Dyslipidemia is one of the four major risk factors for the development of cardiovascular disease, along with hypertension, smoking, and diabetic mellitus. This countrywide study aimed to determine the prevalence and patterns of dyslipidemia and to describe their characteristics using data from the Korean population visiting local clinics. Methods We retrospectively reviewed the lipid profiles (total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC), and triglycerides (TG)) and fasting plasma glucose (FPG) test results from Korean patients visiting local clinics during December 2023. Dyslipidemia was defined as having one or more of TC ≥200 mg/dl, LDLC ≥100 mg/dl, HDLC &amp;lt;40 mg/dl for males and &amp;lt;50 mg/dl for females, or TG ≥150 mg/dl (National Cholesterol Education Program, Adult Training Program III, 2002). Glucose levels are considered hyperglycemic if blood glucose ≥126 mg/dl. The subjects comprised 1,232 patients who visited 57 local clinics nationwide were included. Lipid profile tests (except LDLC) and FPG were performed on Hitachi008AS automatic biochemistry analyzer and the LDLC test was calculated by the Friedewald equation. Data for TG ≥400 mg/dL were excluded. Results The study subject population comprised 610 males and 622 females aged 2 to 91 years. The overall prevalence of dyslipidemia was 53.3% (657/1,232), with 49.3% (301/657) males and 57.2 (356/657) females (p&amp;lt;0.001). TC, LDLC, and TG were high in 14.5% (95/657), 33.9% (184/657), and 23.6% (223/657) of patients, respectively; HDLC was low in 28.0% (155/657). The prevalence of dyslipidemia by age group was as follows: 2 to 19 years (36.4%, 4/11); 20 to 29 years (66.7%, 12/18); 30 to 39 years (52.5%, 52/99); 40 to 49 years (61.5%, 131/213); 50 to 59 years (57.0%, 167/293); 60 to 69 years (50.1%, 168/335); 70 to 79 years (48.4%, 91/188); 80 years or older, (42.7%, 32/75). There was a difference in the prevalence of dyslipidemia between the age group under 50 and the age group over 50 (p&amp;lt;0.001). The prevalence of dyslipidemia among males and females was TC (72.6% vs 28.4%), HDLC (55.4% vs 44.6%), LDLC (53.8% vs 46.2%), TG (42.6% vs 57.4%), respectively (p&amp;lt;0.001). Thirteen of the 1,232 patients had dyslipidemia accompanied by hyperglycemia. Seven of them had mixed dyslipidemia (including raised TC, LDLC, and TG (n=4), raised TG &amp; Low HDLC (n=2), raised TC and LDLC (n=1)). Conclusions The prevalence of dyslipidemia in Korean patients visiting local clinics was 53.3% and differed by gender, age group, and lipid profile. Considering that the prevalence of dyslipidemia is higher in diabetic patients compared to patients without diabetes, additional studies targeting a large number of patients are needed to promote disease prevention and control.

Muscle strength as a marker of metabolic health in kidney transplant recipients: A cross-sectional study

BackgroundMuscle strength is often used as an indirect indicator of metabolic health across different age groups in healthy individuals. However, in kidney transplant recipients, this measure may be less accurate due to metabolic changes induced by immunosuppressive medications. AimTo compare muscle strength between kidney transplant recipients with metabolic syndrome (MS) and those without this condition. MethodsA cross-sectional analytical study was conducted with 29 participants (22 men and seven women) aged 18–50 years, having undergone a kidney transplant for over a year and without experiencing graft failure. To determine the presence of MS, the criteria proposed by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP-III) was used. Biochemical markers (triglyceride, total cholesterol, HDL, LDL, and glucose levels) were evaluated through a capillary sample. Muscle strength was assessed through three tests: long jump, elbow flexion, and grip strength. ResultsThe mean age was 36 ± 11.3 years, and the average transplant time was 4.5 ± 2.8 years. The prevalence of MS was 58.6%. Transplant recipients with MS performed less in all tests assessing muscle strength than those without this condition (p < 0.001∗). ConclusionsThe main finding of this research is that kidney transplant patients with MS performed worse in muscle strength tests compared to those without the condition.

.

Background: Dyslipidaemia has been proposed as a potential risk factor for breast cancer. This study aimed to evaluate the association between serum lipid profiles and breast cancer among women, comparing lipid levels between breast cancer patients and healthy controls. Methods: A hospital-based cross-sectional observational study was conducted at SMS Medical College and Hospital, Jaipur, from ethics committee approval until June 2024. The study included 100 breast cancer patients and 100 matched healthy controls. Inclusion criteria were individuals aged 18 years or older with informed consent, while exclusion criteria included critically ill patients, those with malignancies other than breast cancer, and those on lipid-lowering therapy. The lipid profile was assessed according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines. Data collection involved clinical examination, anthropometric measurements, and biochemical analysis of serum lipid levels. Results: The mean age of participants was 48.5 years for the Case Group and 45.92 years for the Control Group. Serum lipid profiles showed significantly higher levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and triglycerides (TG) in breast cancer patients compared to controls, with TC at 197 ± 42.2 mg/dl vs. 174.06 ± 38.46 mg/dl, LDL at 152.65 ± 32.57 mg/dl vs. 121.09 ± 24.56 mg/dl, and TG at 162.12 ± 15.64 mg/dl vs. 138.23 ± 22.99 mg/dl. High-density lipoprotein cholesterol (HDL) was significantly lower in breast cancer patients (36.0 ± 16.60 mg/dl vs. 50.60 ± 17.64 mg/dl). Subgroup analysis by age showed similar trends across different age groups. No significant differences were observed between premenopausal and postmenopausal women in lipid levels. Conclusion: Elevated serum lipid levels, particularly TC, LDL, and TG, are associated with breast cancer. Monitoring and managing lipid levels may offer potential benefits in breast cancer prevention and treatment strategies.

Vitality and metabolic responses to integrated naturopathy and yogic interventions among metabolic syndrome – A protocol for randomized controlled trial

BackgroundMetabolic Syndrome (MetS) refers to a collection of interrelated physiological, biochemical, clinical, and metabolic variables that significantly raise the risk of type 2 diabetes, cardiovascular disease, and all-cause mortality. This trial aims to assess the effect of Naturopathy and Yogic Interventions on Vitality and Metabolic responses among patients with MetS. MethodThis trial is a single Centre Randomized Controlled Trial (RCT) and will be conducted at Nature Cure and Yoga Centre in the Southern part of India. Enrolled subjects with MetS, who fulfilled National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III Criteria], will be randomly allocated at a 1:1 ratio into Intervention and control groups. The Intervention group will receive Intensive Naturopathy and Yoga Intervention whereas the control group will receive a lifestyle advice during the initial consultation. The primary outcome will be measured by Heart Rate Variability (HRV), Blood Pressure Measurement, Biochemical Analysis, Anthropometric Measurement, Vitality Questionnaire, and Framingham Risk Score (FRS) which will be performed at the baseline and after 10 days of intervention and follow up will be taken at the 60th day. DiscussionA larger clinical trial will be possible as a result of this study's contribution to the understanding of the effectiveness of Yogic Interventions and Integrated Naturopathy for MetS and associated risk factors.

Association of physical activity and risk of cardiac disease among adults

Background: Nowadays the level of physical activity is compromised among all, especially in young adults, which may contribute to early development risk of cardiac disease. Objective: To determine the association of risk of cardiac disease with physical activity among young adults. Methods: A cross-sectional study was conducted from January 2024 to April 2024 at Iqra National University, Peshawar after approval from the ethical committee. A total of n=102 undergraduate male and female students between the age of 18-24 years were included in the study. To determine the physical activity of the participants International Physical Activity Questionnaire - Short Form was used. To evaluate the risk of cardiac disease was observed according to the National Cholesterol Education Program. Results: The mean age and BMI of the n=102 study participants were 23.22±3.4 years and 23.37±5kg/m2 respectively. The risk of cardiac disease was found in n=45(44.1%) while most of the participants (n=33) were moderately and (n=42) highly physically active with a mean METs score of 2881.51±2704.83. Physical activity (PA) is not significantly associated (p=0.44) with the risk of cardiac disease. However, gender showed a strong association (p&lt;0.001) with the risk of cardiac disease among the participants. A total of n=24(88.8%) females had the risk, out of n=27, while n=21(28%) males had the risk of cardiac disease out of n=75 males. Conclusion: The study concluded that physical activity had a non-significant relation with the risk of cardiac disease while in the case of gender females are more prone to have the risk of cardiac disease. Keywords: Cardiac diseases, physical activity, risk factors

Association between Metabolic Syndrome and the Severity of Ischemic Heart Disease

Ischemic Heart Disease (IHD) was a leading cause of mortality worldwide, often complicated by metabolic syndrome, which includes hypertension, hyperglycemia, and dyslipidemia. Objective: To investigate the association between metabolic syndrome and the severity of ischemic heart disease. Methods: Data were collected from the cohort’s existing records, including clinical assessments, laboratory tests, and self-reported questionnaires. Metabolic syndrome components were evaluated using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Participants were classified as having metabolic syndrome if they met three or more of the following criteria: abdominal obesity, elevated blood pressure, elevated fasting glucose, high triglycerides, and low HDL cholesterol. IHD incidence was determined through medical records, hospital admissions, and mortality data, defined as non-fatal myocardial infarction, unstable angina, or coronary revascularization. Statistical analysis included calculating the incidence rate of IHD for participants with and without metabolic syndrome, expressed as IHD cases per 1,000 person-years. Cox proportional hazards regression models were used to assess the association between metabolic syndrome and IHD incidence, adjusting for confounders such as age, sex, smoking status, physical activity, and family history of cardiovascular disease. Hazard Ratios (HRs) with 95% Confidence Intervals (CIs) were reported. Results: The incidence of IHD was significantly higher in participants with metabolic syndrome. Cox regression showed metabolic syndrome was associated with increased IHD incidence (HR: 2.70, 95% CI: 1.50–4.80, p &lt; 0.001). Conclusion: Metabolic syndrome was significantly associated with IHD incidence. Early identification and management were essential to reduce IHD risk.

Associations between body fat anthropometric indices and mortality among individuals with metabolic syndrome

BackgroundThe distribution of body fat and metabolic health may contribute to the onset of metabolic syndrome (MetS), but the associations between body fat anthropometric indices (AIs) and mortality in individuals with MetS remain unclear.MethodsParticipants aged 18 years or older with MetS were recruited from the NHANES 1999–2018. The body fat anthropometric indices included the a body shape index (ABSI), body roundness index (BRI), cardiometabolic index (CMI), visceral adiposity index (VAI), waist triglyceride index (WTI), lipid accumulation product (LAP), atherogenic index of plasma (AIP), and triglyceride‒glucose (TyG) index. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) criteria. Mortality data were obtained from the National Death Index through December 31, 2019.ResultsData were collected from 8,379 individuals with MetS, with a median follow-up of 8.5 years, of whom 1,698 died from all causes and 568 from the CCD. The random survival forest (RSF) analysis indicated that the ABSI had the strongest predictive power for both all-cause mortality and CCD mortality among the eight body fat AIs. After adjusting for multiple variables, the ABSI was found to be linearly and positively associated with all-cause and CCD mortality in individuals with MetS. Participants in the highest quartile of ABSI had an increased risk of all-cause (HR = 1.773 [1.419–2.215]) and CCD (HR = 1.735 [1.267–2.375]) mortality compared with those in the lowest quartile. Furthermore, the ABSI predicted areas under the curve (AUCs) of 0.735, 0.723, 0.718, and 0.725 for all-cause mortality at 3, 5, 10, and 15 years, respectively, and 0.774, 0.758, 0.725, and 0.715 for CCD mortality, respectively.ConclusionAmong eight body fat AIs, the ABSI exhibited the strongest predictive power for mortality in individuals with MetS. Higher ABSI values significantly increased all-cause mortality and CCD mortality in participants with MetS.

Prevalence Of Metabolic Syndrome in Peri and Postmenopausal Women Aged 40- 65 Years in a Tertiary Care Centre

Metabolic syndrome (MetS) is a constellation of interrelated risk factors of metabolic origin— metabolic risk factors—that appear to directly promote the development of atherosclerotic cardio-vascular disease (ASCVD). Menopausal transition with its incidental hormonal changes is considered to contribute to the development of MetS. This was a hospital based cross sectional descriptive study conducted in the Obstetrics and Gynaecology department of Nepal Medical College Teaching Hospital, Attarkhel, Gokarneshwor-8, Kathmandu, from the 1st of September 2023 till the 29th of February 2024 after clearance from the IRC (Ref. No: 56-080/081). Convenience sampling was used among women who fulfilled the inclusion criteria. The aim of the study was to determine the prevalence of MetS among the peri and postmenopausal women and to determine which component of the diagnostic criteria of MetS was more strongly associated with MetS in our population. Women were evaluated to have MetS using both the International Diabetes Federation (IDF) and the National Cholesterol Education Program- Adult Treatment Panel III (NCEP-ATPIII criteria). The prevalence of MetS by the IDF criteria was 54% among the perimenopausal women and 61% among the postmenopausal women. Similarly, the prevalence of MetS according to NCEP-ATPIII was 53.5% among the perimenopausal and 65% among the postmenopausal women. All the MetS diagnostic markers showed a strong correlation with MetS (p&lt;0.001). The prevalence of MetS is high in our population by both the IDF and NCEP-ATP III criteria, being higher in the postmenopausal population, though not statistically significant.

Metabolic Syndrome and Its Component Factors Among Corporate Company Employees in Kampala Uganda.

Metabolic syndrome (MetS), a cluster of metabolic dysregulations indicative of increased cardiometabolic risk is on the rise in Sub-Saharan Africa. The study aimed to determine the prevalence of MetS and its components, among corporate employees in Kampala, Uganda. A cross-sectional survey was undertaken among 408 adults who were employees from seven corporate companies in Kampala, using the WHO STEPwise NCD screening approach. Metabolic syndrome was measured using the National Cholesterol Education Program Adult Treatment Panel (ATPIII) and the International Diabetes Federation (IDF) criteria with the waist circumference (WC) cut-off points adapted for Sub-Saharan African populations. The mean population age (standard deviation [SD]) of the respondents was 34years (± 8.87) years and 52% of them were females. The prevalence of MetS was 22.8% (NCEP ATPIII) and 28.4% (IDF). Of the respondents who did not have MetS, 75% had at least one metabolic dysregulation. Of those respondents with MetS, only 31% perceived that they were at risk of this cluster of metabolic dysregulations. In this analysis, we observed that the systolic blood pressure (BP) and the body mass index (BMI) correlated strongly (r = 0.81 and r = 0.71) with the diastolic BP and waist circumference (WC), respectively. Age on the other hand correlated fairly with the WC and BMI (both r values = 0.46). Principal component analysis showed that the greatest loadings in principle factors one, two and three were from central obesity, with low HDL-C explaining 60.8% variance in the population. Age, BMI, family history of having cardiometabolic disorders, and perceived cardiometabolic disease risk (CMR) were associated with an increased risk of MetS by 5, 8.86, 1.55, and 2.73 (all P values were < 0.05) respectively in this group of respondents. These risks remained for age, BMI and perceived CMR after removing the confounding effects of education status, marital status and family history of cardiometabolic disease. Being single on the other hand, was associated with a reduced risk of MetS (0.23, p < 0.009). While the primary contributors to the high prevalence of MetS among corporate employees in Kampala, Uganda were the high BP, high WC and high fasting blood sugar (FBS); age, BMI and perceived CMR were the key determinants of MetS. Future MetS interventions should aim to control and monitor obesity indicators in this population. Additionally, the findings inform targeted screening parameters for cardiometabolic risk assessment and suggest the need for further research into a weighted algorithm for MetS in this population.

Metabolic Syndrome and Its Associated Factors Among Patients With Schizophrenia Treated With Second-Generation Antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia.

Background Metabolic syndrome (MetS) encompasses a group of risk factors that increase the likelihood of developing cardiovascular diseases, thereby increasing the mortality rate. Second-generation antipsychotics (SGAs) are known for these side effects. This study aimed to determine the prevalence of MetS and its associated factors at Amanuel Mental Specialized Hospital. Methods A cross-sectional study was conducted from October 3, 2022, to August 31, 2023. Fasting blood sugar and lipid analysis were performed using the Dimension® EXL™ 200 Integrated Chemistry System (Siemens Healthineers, Malvern, PA, USA). A diagnosis of MetS was established using the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) criteria. IBM SPSS Statistics for Windows, Version 25 (Released 2017; IBM Corp., Armonk, NY, USA) was used for analysis. A binary logistic regression model was employed, and a p-value less than 0.05 was considered significant. Results A total of 271 participants were enrolled in the study. Most subjects were male (90%) and had a mean age of 34.2 years, with an SD of 10.5. Most participants (70.8%) had abnormal waist circumference, followed by lower high-density lipoprotein cholesterol (HDL-C) at 42.8%. The prevalence of MetS was 35.8%. Gender (being female) (adjusted odds ratio or AOR 3, 95% CI: 1.2-7.4; p = 0.02) and olanzapine use (AOR 2.2, 95% CI: 1.3-3.7; p = 0.005) were predictors of MetS. Conclusions MetS is highly prevalent in patients treated with SGAs. Being female and olanzapine use were predictors of MetS. Clinicians managing these patients should screen and monitor the metabolic components used to diagnose MetS.

Exploring the link between leptin levels and metabolic syndrome in elderly Indian patients: Implications for family medicine and primary care practices.

The metabolic syndrome (MetS), according to the Adult Treatment Panel III of the National Cholesterol Education Programme, is a collection of metabolic abnormalities that includes one, two, or all three of the following traits: obesity in the abdomen, dyslipidemia, hypertension, fasting blood sugar, or insulin resistance. This study's aim was to assess the relationship between fasting serum leptin and MetS in elderly adults with T2DM in the Northern Indian population. The following information was collected from all the participants: (1) anthropometric data, (2) biochemical data, and (3) a lifestyle questionnaire on sociodemographic data, dietary practices, smoking, and alcohol intake to identify their risk factors for diabetes mellitus, CVD, and hypertension. A total of 36 older participants (56.30%) had a history of hypertension, while 29 elderly participants (44.61%) had diabetes mellitus. A total of 32 elderly participants (49.2%) had MetS, and this group had higher serum leptin (P 0.003), body weight (P = 0.019), BMI (P 0.001), waist circumference (P 0.001), CRP (P = 0.021), insulin (P = 0.001), and HOMA-IR (P = 0.003) values as well as higher percentages of females (P = 0.001), and those with type 2 diabetes mellitus (P = 0.002) and hypertension (P = 0.039) than those in the non-MetS group. In older persons with T2DM, our study discovered a favorable correlation between serum leptin and MetS. It can act as a standalone indicator of MetS, offering a way to spot populations at risk for associated consequences and enabling early intervention.

A Cross-Sectional Study on the Prevalence of Subclinical Hypothyroidism in Metabolic Syndrome Patients at a Tertiary Care Hospital.

Metabolic syndrome (MetS) is defined as a "constellation" of cardiometabolic risk factors, characterized by hypertension, atherogenic dyslipidemia, hyperglycemia, prothrombotic and proinflammatory conditions which, jointly, increase the risk of suffering cardiovascular diseases (CVD) and type 2 diabetes mellitus.Thyroid dysfunction is also believed to affect parameters such as high-density lipoprotein (HDL) cholesterol, triglycerides, plasma glucose, and blood pressure, in turn increasing the risk of CVD. Subclinical hypothyroidism (SCH), which independently raises the risk of CVDs and their associated complications, is more frequently detected in patients with MetS compared to the general population. When both conditions coexist, the risk of CVD and its complications is significantly heightened. The objective of the study was to find out the prevalence of SCH in patients with MetS. A prospective cross-sectional study was conducted in the Department of General Medicine, New Civil Hospital, Surat, Gujarat, India. Eighty patients who fulfilled the criteria for MetS by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), were taken into the study. A detailed history, anthropometric measurements, blood pressure, fasting blood glucose, lipid profile, and thyroid profile (Free T3, Free T4, and serum thyroid-stimulating hormone (TSH)) were undertaken. The thyroid profile was done by chemiluminescence immunoassay (CLIA) method. Out of 80 patients with MetS, 48 were female and 32 were male, with the overall mean age of the study population being 46.5±9.5 years. Among them, 23.7% of the population was found to be having thyroid dysfunction. Among the thyroid dysfunction, SCH was highly prevalent (18.8%), 3.8% patients had overt hypothyroidism and 1.3% patients had subclinical hyperthyroidism. There were no overt hyperthyroid patients in our study.HDL (mg/dl) and TSH (mIU/L) were significantly higher in the SCH group as compared to other types of hypothyroidism group (p-value < 0.05). There is a statistically significant prevalence of SCH (18.8%) in MetS patients. It is clear from the study that one-fifth of MetS patients or every fifth patient with MetS had SCH. Thus, looking proactively for SCH in MetS and treating it would prevent conversion to overt hypothyroidism and complications of MetS.

Prevalence of metabolic syndrome patıents with systemic sclerosis

Objective: To determine the prevalence of metabolic syndrome (MetS) in Turkish systemic sclerosis (SSc) patients. Materials and Methods: In this cross-sectional, single-centre study, 76 SSc patients admitted to the outpatient clinic of our tertiary care hospital between July and September 2021 were included. The National Cholesterol Education Programme's Adult Treatment Panel (NCEP-ATP III) criteria were used to define metabolic syndrome (MetS). The relationship between MetS and SSc organ involvement and disease characteristics was investigated. Results: According to the ATP III criteria, 37 cases (48.7%) were identified as having MetS. The prevalance of MetS increased with advancing age (40-45 years: 25%, 46-60 years: 48.4%, &amp;gt;60 years: 62.9%). The cases were divided into two groups according to the presence or absence of MetS. Patients with MetS had higher mean age (58.2±9.4 vs. 51.6±13.5, p=0.015) and lower modified Rodnan skin scores (14 vs. 22, p=0.019). The groups were comparable regarding disease subtype, duration and activity, organs/systems involved and disease-related damage. Conclusion: Although the prevalence of MetS in SSc patients in our study was higher than that observed in the general population of our country, the prevalence of MetS did not increase when compared to the similar age group. MetS was thought to be related to age and gender predominance rather than the disease itself. Although mRSS was found to be significantly lower in patients with MetS, its sensitivity to predict MetS was found to be low. Nevertheless, our data suggest that the risk of MetS should be considered in SSc patients.

Comparison of cardiovascular disease risk association with metabolic unhealthy obesity identified by body fat percentage and body mass index: Results from the 1999-2020 National Health and Nutrition Examination Survey.

Cardiovascular disease (CVD) risk among individuals across different categories of metabolic obesity phenotypes is controversial. The study used body fat percentage (BFP) or body mass index (BMI) to categorize obese status and to investigate the association between metabolic obesity phenotypes and CVD risk in a nationally representative population. This cross-sectional study included 49463 adult participants in National Health and Nutrition Examination Survey from 1999 to 2020. Metabolic healthy status was defined by the absence of metabolic syndrome according to the revised National Cholesterol Education Program Adult Treatment Group definition. Obesity was identified by BFP, assessed by dual-energy X-ray absorptiometry scan, and BMI. The primary outcome was CVD prevalence. The multivariable logistic regression model and restricted cubic spline analyses were used to examine the associations between metabolic obesity phenotypes and the risk of CVD. Among 49463 adult participants, 32.12% were metabolically unhealthy, 34.10% were overweight, 37.94% were obese; and 8.41% had CVD. Compared with metabolic healthy normal weight, metabolic healthy obesity, and metabolic unhealthy normal weight/overweight/obesity were all associated with increased CVD risk with adjusted odds ratios (95% confidence intervals) of 1.45 (1.14-1.85), 2.80(1.53-5.11), 2.55(1.88-3.47), and 2.96(2.18-4.02), respectively. Nonlinear dose-response relationships between BFP and CVD were observed both in metabolically healthy and unhealthy participants (both P for non-linearity<0.0001). When obesity was defined with BMI, there were a similar prevalence of obesity, and similar associations between metabolic obesity phenotypes and CKD risks. Metabolic healthy and unhealthy obesity were both associated with higher risks of CVD, whether using BFP or BMI to define obese status. It suggests that metabolic obesity phenotype is a risk factor for CVD.

Efficacy of tryushnadya churna in metabolic syndrome with obesity – A randomized double blind controlled clinical trial

Metabolic syndrome (MetS) with obesity has significant mortality and morbidity. Integrative Ayurveda management is explored for it's possible effect. To evaluate the effect of Tryushnadi churna in the management of Metabolic syndrome with obesity. Study is a Randomized, Controlled, double blind, parallel group comparative clinical trial. 48 participants meeting the National Cholesterol Education Programme Adult Treatment panel 3 diagnostic criteria were recruited in the study. They were divided in two 2 groups. Placebo group were administered with Placebo 1gm twice a day, Ayurveda diet and yoga. Tryushnadi Group were intervened with Tryushnadi churna 1gm twice a day, Ayurveda diet and yoga. Interventions were for 90 days. Assessments criteria included Weight, BMI,Waist circumference (WC), Waist hip ratio, Skin fold thickness (SFT), Body fat, blood pressure, WHO-QOL BREF scale, Clinical Global Impression Scale (CGI)- Severity, Global improvement and Efficacy index, Fasting blood sugar (FBS) were assessed on every 30th day. Other blood parameters like Glycated haemoglobin (HbA1c), Triglycerides, High density lipoproteins (HDL), Low density lipoproteins (LDL), Total cholesterol (TC) were evaluated at pre and post study. Between groups comparison showed, Tryushnadi group had significant improvements in BMI, Weight, WHOQOL-Bref and had large effect size. Both the groups showed improvement in WC, body fat, SFT, CGI severity, CGI efficacy index and improvement in quality of life in within group assessment. Study showed that Tryushnadi churna was effective in management of MetS with Obesity. Integrated management of Ayurveda medicine, Ayurveda diet and yoga had beneficial effect.